Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 7/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414174 | 0.88 | FBP1 (0.49) | FBP1TSHRPPARAABCB11CYP1A2 | |
| SCHEMBL4677347 | 0.86 | FBP1 (0.55) | FBP1TSHRSMN1; SMN2PPARAABCB11 | |
| SCHEMBL14445933 | 0.82 | FBP1 (0.52) | FBP1TSHRSMN1; SMN2PPARAABCB11 | |
| SCHEMBL4679282 | 0.82 | FBP1 (0.51) | FBP1TSHRSMN1; SMN2PPARAABCB11 | |
| SCHEMBL4678053 | 0.82 | FBP1 (0.58) | FBP1TSHRSMN1; SMN2PPARAABCB11 | |
| SCHEMBL14445931 | 0.81 | FBP1 (0.50) | FBP1TSHRSMN1; SMN2PPARAABCB11 | |
| SCHEMBL4682002 | 0.81 | FBP1 (0.57) | FBP1TSHRSMN1; SMN2PPARAABCB11 | |
| SCHEMBL4681433 | 0.81 | PPARA (0.58) | FBP1TSHRPPARAABCB11CYP1A2 | |
| SCHEMBL6740992 | 0.79 | FBP1 (0.55) | FBP1TSHRSMN1; SMN2PPARAABCB11 | |
| SCHEMBL4735996 | 0.79 | LMNA (0.41) | TSHRSMN1; SMN2PPARAGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513796-B1 | PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORP (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7241793-B2 | Phenyloxyalkanonic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | SMITHKLINE BEECHAM CORPORATION | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | CEL, HPN, LIPA | FBP1 393/4885TSHR 2419/4885SMN1; SMN2 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.